ESMO 2021: Addition of Taselisib to Tamoxifen Is Effective but Toxic in HR-Positive, HER2-Negative Metastatic Breast Cancer
Findings suggest the target is correct but better tolerated drugs are needed
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.